REGENXBIO Inc. (FRA:RB0)

Market Cap	475.52M +32.7%
Revenue (ttm)	137.49M +91.3%
Net Income	-151.64M
EPS	-2.95
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	44
Open	11.60
Previous Close	13.50
Day's Range	11.60 - 11.60
52-Week Range	4.68 - 13.60
Beta	n/a
RSI	37.53
Earnings Date	Feb 24, 2026

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 353
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RB0

Financial Performance

In 2024, REGENXBIO's revenue was $83.33 million, a decrease of -7.66% compared to the previous year's $90.24 million. Losses were -$227.10 million, -13.81% less than in 2023.

Financial numbers in USD